Ramesh N. Patel
Ramesh N. Patel has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Amit Banerjee
Bristol-Myers Squibb Pharmaceutical Research Institute
3 shared publicationsAnimesh Goswami
Chemistry Technology, Process Research and Development, Bristol-Myers Squibb Pharmaceutical Research Institute, New Brunswick, NJ 08903, United States
3 shared publicationsSteven Goldberg
Chemistry Technology, Process Research and Development, Bristol-Myers Squibb Pharmaceutical Research Institute, New Brunswick, NJ 08903, United States
2 shared publicationsVenkata Nanduri
Bristol-Myers Squibb Pharmaceutical Research Institute
2 shared publicationsChien-Kuang Chen
Department of Microbial Technology and Process Development, Process Research & Development, Bristol-Myers Squibb Pharmaceutical Research Institute, P.O. Box 191, New Brunswick, NJ 08903, USA
1 shared publicationClyde G McNamee
Department of Microbial Technology and Process Development, Process Research & Development, Bristol-Myers Squibb Pharmaceutical Research Institute, P.O. Box 191, New Brunswick, NJ 08903, USA
1 shared publication
Latest Publications
- 25 February 2008
- Published by Wiley
- Vol. 9 (6) , 319-353
Biocatalysis: Synthesis of Chiral Intermediates for Drugs
This chapter contains sections titled: Introduction Enantioselective enzymatic reductive amination of 2‐(3‐hydroxy‐1‐adamantyl)‐2‐oxoethanoic acid Regioselective enzymatic acylation of ribavirin Microbial hydroxylation of epothiolone B Biohydroxylation 2‐cyclopentylbenzoxazole Enzymatic preparation of 6‐hydroxybuspirone Enzymatic preparation of (s)‐2‐chloro‐1‐(3‐chlorophenyl)ethanol Stereospecific microbial reduction of ethyl 1‐benzyl‐3‐oxo‐piperidine‐4‐carboxylate Enzymatic preparation of a prodrug of 9‐β‐D‐arabinofuranosyl guanine Enzymatic desymmetrization of diethyl 3‐[3′,4′‐dichlorophenyl]glutarate Enzymatic synthesis of intermediates for propanolol and denopamine Biocatalytic asymmetric dihydroxylation Enzymatic synthesis of ethyl (3R,5S)‐dihydroxy‐6‐(benzyloxy) hexanoate Enzymatic preparation of a 2,4‐dideoxyhexose derivative Enzymatic preparation of (R)‐4‐cyano‐3‐hydroxybutyrate Enzymatic synthesis of chiral carboxylic acids Enzymatic resolution of α‐methyl‐1,3‐benzodioxole‐5‐ethanol Enantioselective enzymatic reduction of N,N‐dimethyl‐3‐keto‐3‐(2‐thienyl)‐1‐propanamine Dynamic kinetic resolution (DKR) Conclusions References
- 25 February 2008
- Published by Wiley
- Vol. 9 (6) , 319-353
Biocatalysis: Synthesis of Chiral Intermediates for Drugs
This chapter contains sections titled: Introduction Enantioselective enzymatic reductive amination of 2‐(3‐hydroxy‐1‐adamantyl)‐2‐oxoethanoic acid Regioselective enzymatic acylation of ribavirin Microbial hydroxylation of epothiolone B Biohydroxylation 2‐cyclopentylbenzoxazole Enzymatic preparation of 6‐hydroxybuspirone Enzymatic preparation of (s)‐2‐chloro‐1‐(3‐chlorophenyl)ethanol Stereospecific microbial reduction of ethyl 1‐benzyl‐3‐oxo‐piperidine‐4‐carboxylate Enzymatic preparation of a prodrug of 9‐β‐D‐arabinofuranosyl guanine Enzymatic desymmetrization of diethyl 3‐[3′,4′‐dichlorophenyl]glutarate Enzymatic synthesis of intermediates for propanolol and denopamine Biocatalytic asymmetric dihydroxylation Enzymatic synthesis of ethyl (3R,5S)‐dihydroxy‐6‐(benzyloxy) hexanoate Enzymatic preparation of a 2,4‐dideoxyhexose derivative Enzymatic preparation of (R)‐4‐cyano‐3‐hydroxybutyrate Enzymatic synthesis of chiral carboxylic acids Enzymatic resolution of α‐methyl‐1,3‐benzodioxole‐5‐ethanol Enantioselective enzymatic reduction of N,N‐dimethyl‐3‐keto‐3‐(2‐thienyl)‐1‐propanamine Dynamic kinetic resolution (DKR) Conclusions References
- 25 January 2008
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 3 (2) , 187-245
Chemo-enzymatic synthesis of pharmaceutical intermediates
(2008). Chemo-enzymatic synthesis of pharmaceutical intermediates. Expert Opinion on Drug Discovery: Vol. 3, No. 2, pp. 187-245. doi: 10.1517/17460441.3.2.187
- 25 January 2008
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 3 (2) , 187-245
Chemo-enzymatic synthesis of pharmaceutical intermediates
(2008). Chemo-enzymatic synthesis of pharmaceutical intermediates. Expert Opinion on Drug Discovery: Vol. 3, No. 2, pp. 187-245. doi: 10.1517/17460441.3.2.187
- 1 May 2003
- Published by Oxford University Press (OUP) in Journal of Industrial Microbiology and Biotechnology
- Vol. 30 (5) , 252-259
Enzymatic synthesis of chiral intermediates for pharmaceuticals
There has been an increasing awareness of the enormous potential of microorganisms and enzymes for the transformation of synthetic chemicals with high chemo-, regio- and enatioselective manner. Chiral intermediates are in high demand by pharmaceutical industries for the preparation bulk drug substances. In this review article, microbial/enzymatic processes for the synthesis of chiral intermediates for antihypertensive drugs, melatonin receptor agonists, and β3-receptor receptor agonists are described.
- 1 May 2003
- Published by Oxford University Press (OUP) in Journal of Industrial Microbiology and Biotechnology
- Vol. 30 (5) , 252-259
Enzymatic synthesis of chiral intermediates for pharmaceuticals
There has been an increasing awareness of the enormous potential of microorganisms and enzymes for the transformation of synthetic chemicals with high chemo-, regio- and enatioselective manner. Chiral intermediates are in high demand by pharmaceutical industries for the preparation bulk drug substances. In this review article, microbial/enzymatic processes for the synthesis of chiral intermediates for antihypertensive drugs, melatonin receptor agonists, and β3-receptor receptor agonists are described.
- 1 December 2001
- Published by Elsevier in Current Opinion in Biotechnology
- Vol. 12 (6) , 587-604
Biocatalytic synthesis of intermediates for the synthesis of chiral drug substances
- 1 December 2001
- Published by Elsevier in Current Opinion in Biotechnology
- Vol. 12 (6) , 587-604
Biocatalytic synthesis of intermediates for the synthesis of chiral drug substances
- 28 August 2001
- Published by Wiley in Advanced Synthesis & Catalysis
- Vol. 343 (6-7) , 527-546
Enzymatic Synthesis of Chiral Intermediates for Drug Development
- 28 August 2001
- Published by Wiley in Advanced Synthesis & Catalysis
- Vol. 343 (6-7) , 527-546
Enzymatic Synthesis of Chiral Intermediates for Drug Development
- 1 June 2001
- Published by Elsevier in Biomolecular Engineering
- Vol. 17 (6) , 167-182
Enzymatic synthesis of chiral intermediates for Omapatrilat, an antihypertensive drug
- 1 June 2001
- Published by Elsevier in Biomolecular Engineering
- Vol. 17 (6) , 167-182
Enzymatic synthesis of chiral intermediates for Omapatrilat, an antihypertensive drug
- 1 October 2000
- Published by Wiley in Journal of the American Oil Chemists' Society
- Vol. 77 (10) , 1015-1019
Enzymatic resolution of racemic secondary alcohols by lipase B from Candida antarctica
Chiral intermediates S‐(+)‐2‐pentanol and S‐(+)‐2‐heptanol were prepared by a lipase‐catalyzed enzymatic resolution proces. Among various lipases evaluated for the stereoselective acylation of racemic alcohols, lipase B from Candida antarctica catalyzed the acylation of the undesired enantiomer of racemic alcohols leaving the desired S‐(+)‐alcohols unreacted. A reaction yield of 43–45% and an enantiomeric excess (e.e.) of >99% were obtained for S‐(+)‐2‐pentanol or S‐(+)‐2‐heptanol when the reaction was carried out using vinyl acetate or succnic anhydride as acylating agent. In an alternative process, an enantioselective hydrolysis of 2‐pentyl acetate was demonstrated using lipase B giving S‐(+)‐2‐pentyl acetate and R‐(−)‐2‐pentanol. A reaction yield of 45% and an e.e. of 98.6% were obtained for S‐(+)‐2‐pentyl acetate.
- 1 October 2000
- Published by Wiley in Journal of the American Oil Chemists' Society
- Vol. 77 (10) , 1015-1019
Enzymatic resolution of racemic secondary alcohols by lipase B from Candida antarctica
Chiral intermediates S‐(+)‐2‐pentanol and S‐(+)‐2‐heptanol were prepared by a lipase‐catalyzed enzymatic resolution proces. Among various lipases evaluated for the stereoselective acylation of racemic alcohols, lipase B from Candida antarctica catalyzed the acylation of the undesired enantiomer of racemic alcohols leaving the desired S‐(+)‐alcohols unreacted. A reaction yield of 43–45% and an enantiomeric excess (e.e.) of >99% were obtained for S‐(+)‐2‐pentanol or S‐(+)‐2‐heptanol when the reaction was carried out using vinyl acetate or succnic anhydride as acylating agent. In an alternative process, an enantioselective hydrolysis of 2‐pentyl acetate was demonstrated using lipase B giving S‐(+)‐2‐pentyl acetate and R‐(−)‐2‐pentanol. A reaction yield of 45% and an e.e. of 98.6% were obtained for S‐(+)‐2‐pentyl acetate.
- 7 August 2000
- Published by Elsevier in Enzyme and Microbial Technology
- Vol. 27 (6) , 376-389
Biocatalytic preparation of a chiral synthon for a vasopeptidase inhibitor: enzymatic conversion of N2-[N-Phenylmethoxy)carbonyl] L-homocysteinyl]- L-lysine (1- > 1′)-disulfide to [4S-(4I,7I,10aJ)] 1-octahydro-5-oxo-4-[phenylmethoxy)carbonyl]amino]-7H-pyrido-[2,1-b] [1,3]thiazepine-7-carboxylic acid methyl ester by a novel L-lysine ϵ-aminotransferase
- 7 August 2000
- Published by Elsevier in Enzyme and Microbial Technology
- Vol. 27 (6) , 376-389
Biocatalytic preparation of a chiral synthon for a vasopeptidase inhibitor: enzymatic conversion of N2-[N-Phenylmethoxy)carbonyl] L-homocysteinyl]- L-lysine (1- > 1′)-disulfide to [4S-(4I,7I,10aJ)] 1-octahydro-5-oxo-4-[phenylmethoxy)carbonyl]amino]-7H-pyrido-[2,1-b] [1,3]thiazepine-7-carboxylic acid methyl ester by a novel L-lysine ϵ-aminotransferase
- 1 November 1999
- Published by Wiley in Journal of the American Oil Chemists' Society
- Vol. 76 (11) , 1275-1281
Biocatalytic synthesis of chiral intermediates for antiviral and antihypertensive drugs
The chiral intermediate (1S,2R) [3‐chloro‐2‐hydroxy‐1‐(phenylmethyl)propyl] carbamic acid, 1,1‐dimethylethyl ester 2a was prepared for the total synthesis of a human immunodeficiency virus protease inhibitor, BMS‐186318. The stereoselective reduction of (1S) [3‐chloro‐2‐oxo‐1(phenylmethyl)propyl] carbamic acid, 1,1‐dimethylethyl ester 1 was carried out using microbial cultures, among which Streptomyces nodosus SC 13149 efficiently reduced 1 to 2a. A reaction yield of 80%, enantiomeric excess (e.e.) of 99.8%, and diastereomeric purity of 99% were obtained for chiral alcohol 2a. Chiral l‐6‐hydroxy norleucine 3, an intermediate in the synthesis of antihypertensive drug, was prepared by reductive amination of 2‐keto‐6‐hydroxyhexanoic acid 4 using beef liver glutamate dehydrogenase. The cofactor NADH required for this reaction was regenerated using glucose dehydrogenase from Bacillus sp. A reaction yield of 80% and e.e. of 99.5% were obtained for l‐6‐hydroxynorleucine 3. To avoid the lengthy chemical synthesis of the ketoacid, a second route was developed in which racemic 6‐hydroxynorleucine [readily available from hydrolysis of 5‐(4‐hydroxybutyl) hydantoin 5] was treated with d‐amino acid oxidase from Trigonopsis variabilis to selectively convert the d‐isomer of racemic 6‐hydroxynorleucine to 2‐keto‐6‐hydroxyhexanoic acid 4 and l‐6‐hydroxynorleucine 3. Subsequently, the 2‐keto‐6‐hydroxyhexanoic acid 4 was converted to l‐6‐hydroxynorleucine by reductive amination using glutamate dehydrogenase. A reaction yield of 98% and an e.e. of 99.5% were obtained.
- 1 November 1999
- Published by Wiley in Journal of the American Oil Chemists' Society
- Vol. 76 (11) , 1275-1281
Biocatalytic synthesis of chiral intermediates for antiviral and antihypertensive drugs
The chiral intermediate (1S,2R) [3‐chloro‐2‐hydroxy‐1‐(phenylmethyl)propyl] carbamic acid, 1,1‐dimethylethyl ester 2a was prepared for the total synthesis of a human immunodeficiency virus protease inhibitor, BMS‐186318. The stereoselective reduction of (1S) [3‐chloro‐2‐oxo‐1(phenylmethyl)propyl] carbamic acid, 1,1‐dimethylethyl ester 1 was carried out using microbial cultures, among which Streptomyces nodosus SC 13149 efficiently reduced 1 to 2a. A reaction yield of 80%, enantiomeric excess (e.e.) of 99.8%, and diastereomeric purity of 99% were obtained for chiral alcohol 2a. Chiral l‐6‐hydroxy norleucine 3, an intermediate in the synthesis of antihypertensive drug, was prepared by reductive amination of 2‐keto‐6‐hydroxyhexanoic acid 4 using beef liver glutamate dehydrogenase. The cofactor NADH required for this reaction was regenerated using glucose dehydrogenase from Bacillus sp. A reaction yield of 80% and e.e. of 99.5% were obtained for l‐6‐hydroxynorleucine 3. To avoid the lengthy chemical synthesis of the ketoacid, a second route was developed in which racemic 6‐hydroxynorleucine [readily available from hydrolysis of 5‐(4‐hydroxybutyl) hydantoin 5] was treated with d‐amino acid oxidase from Trigonopsis variabilis to selectively convert the d‐isomer of racemic 6‐hydroxynorleucine to 2‐keto‐6‐hydroxyhexanoic acid 4 and l‐6‐hydroxynorleucine 3. Subsequently, the 2‐keto‐6‐hydroxyhexanoic acid 4 was converted to l‐6‐hydroxynorleucine by reductive amination using glutamate dehydrogenase. A reaction yield of 98% and an e.e. of 99.5% were obtained.